StockNews.com Upgrades Chimerix (NASDAQ:CMRX) to “Hold”

Chimerix (NASDAQ:CMRXGet Free Report) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other research firms have also recently issued reports on CMRX. Wedbush reissued an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research note on Monday, February 12th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research note on Friday, March 1st.

Read Our Latest Stock Report on CMRX

Chimerix Stock Up 4.8 %

Shares of Chimerix stock opened at $0.96 on Wednesday. Chimerix has a 12 month low of $0.88 and a 12 month high of $1.57. The business has a fifty day simple moving average of $0.97 and a 200 day simple moving average of $1.00. The stock has a market cap of $86.39 million, a PE ratio of -1.04 and a beta of 1.13.

Chimerix (NASDAQ:CMRXGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. During the same period last year, the firm earned ($0.24) EPS. Analysts expect that Chimerix will post -0.85 EPS for the current fiscal year.

Institutional Trading of Chimerix

A number of institutional investors have recently modified their holdings of the company. RA Capital Management L.P. bought a new stake in shares of Chimerix in the third quarter valued at about $6,240,000. Acadian Asset Management LLC lifted its holdings in shares of Chimerix by 15.5% in the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after purchasing an additional 291,981 shares in the last quarter. Vestal Point Capital LP bought a new stake in Chimerix during the fourth quarter worth about $1,348,000. Bank of New York Mellon Corp raised its holdings in Chimerix by 190.0% during the third quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 387,638 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Chimerix by 17.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after acquiring an additional 72,719 shares in the last quarter. 45.42% of the stock is currently owned by institutional investors.

About Chimerix

(Get Free Report)

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.

Featured Articles

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.